Novartis: promising data in prostate cancer
(CercleFinance.com) - Novartis announced on Monday that a phase III trial of Pluvicto in metastatic prostate cancer had met its primary endpoint.
The study showed that Pluvicto reduced the risk of radiological disease progression (rPFS) by 59% compared with switching to anti-androgens.
Survival without radiological disease progression more than doubled to 12 months, compared with 5.6 months in the control group.
This data, which the study's principal investigator describes as "impressive", was presented at the European Society of Oncology (ESMO) congress on Monday.
Patients with metastatic prostate cancer currently only have a five-year survival rate of around 30%.
Novartis previously announced plans to file regulatory submissions in this indication by the end of the year.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The study showed that Pluvicto reduced the risk of radiological disease progression (rPFS) by 59% compared with switching to anti-androgens.
Survival without radiological disease progression more than doubled to 12 months, compared with 5.6 months in the control group.
This data, which the study's principal investigator describes as "impressive", was presented at the European Society of Oncology (ESMO) congress on Monday.
Patients with metastatic prostate cancer currently only have a five-year survival rate of around 30%.
Novartis previously announced plans to file regulatory submissions in this indication by the end of the year.
Copyright (c) 2023 CercleFinance.com. All rights reserved.